Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Qiagen ( (QGEN) ) has issued an announcement.
The Netherlands Authority for the Financial Markets (AFM) has notified QIAGEN N.V. about a voting rights announcement involving Barclays Plc. The notification, disclosed on the AFM website, details various shareholdings and voting rights held indirectly by Barclays through different financial instruments. This announcement highlights Barclays’ capital interest and voting rights in QIAGEN, which could have implications for the company’s shareholder dynamics and market perception.
The most recent analyst rating on (QGEN) stock is a Buy with a $52.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. operates in the biotechnology industry, focusing on providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is based in Venlo, Netherlands, and is listed on multiple stock exchanges including Frankfurt, NYSE, SIX, and BX Swiss.
Average Trading Volume: 1,444,451
Technical Sentiment Signal: Buy
Current Market Cap: $9.81B
Learn more about QGEN stock on TipRanks’ Stock Analysis page.